Vanguard Group Inc. Has $264.93 Million Stock Position in CG Oncology, Inc. $CGON

Vanguard Group Inc. boosted its position in shares of CG Oncology, Inc. (NASDAQ:CGON) by 11.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,577,281 shares of the company’s stock after purchasing an additional 670,770 shares during the period. Vanguard Group Inc. owned about 8.63% of CG Oncology worth $264,933,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of CG Oncology in the first quarter valued at approximately $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in CG Oncology by 18.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock valued at $876,000 after purchasing an additional 5,442 shares in the last quarter. Millennium Management LLC raised its position in CG Oncology by 139.4% in the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after purchasing an additional 347,055 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in CG Oncology by 42.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock worth $4,393,000 after purchasing an additional 53,461 shares in the last quarter. Finally, Winthrop Capital Management LLC bought a new stake in shares of CG Oncology during the second quarter worth $38,000. 26.56% of the stock is owned by institutional investors.

Analyst Ratings Changes

CGON has been the subject of a number of research analyst reports. Wedbush started coverage on CG Oncology in a report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price target for the company. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $82.00 target price on shares of CG Oncology in a research note on Monday, January 12th. Morgan Stanley set a $93.00 target price on shares of CG Oncology in a research report on Friday, January 9th. HC Wainwright raised their price target on shares of CG Oncology from $75.00 to $80.00 and gave the company a “buy” rating in a report on Friday. Finally, Truist Financial boosted their price objective on shares of CG Oncology from $66.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CG Oncology presently has an average rating of “Moderate Buy” and an average target price of $69.00.

Insider Activity

In related news, Director James Mulay sold 11,145 shares of CG Oncology stock in a transaction on Friday, January 9th. The stock was sold at an average price of $52.47, for a total transaction of $584,778.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.40% of the stock is owned by corporate insiders.

CG Oncology Price Performance

CGON opened at $58.80 on Friday. The company has a market cap of $4.74 billion, a price-to-earnings ratio of -28.41 and a beta of 1.32. The firm has a 50 day simple moving average of $50.42 and a 200 day simple moving average of $42.20. CG Oncology, Inc. has a fifty-two week low of $14.80 and a fifty-two week high of $60.00.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, February 27th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The business had revenue of $2.32 million during the quarter. As a group, analysts expect that CG Oncology, Inc. will post -1.31 EPS for the current year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.